Arndt Vogel, Managing Senior Consultant and a Professor in the Department of Gastroenterology, Hepatology, and Endocrinology at Hannover Medical School, shared a post on X:
“Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma
HEPATORCH phs 3 trial
supports anti-VEGF and ICI combinations
Inline with IMbrave150, CARES-310 and ORIENT-32
Title: Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial
Authors: Yinghong Shi, Guohong Han, Jian Zhou, Xuetao Shi, Weidong Jia, Ying Cheng, Yongdong Jin, Xiangdong Hua, Tianfu Wen, Jianbing Wu, Shanzhi Gu, Yuxian Bai, Xiangcai Wang, Tao Zhang, Zhiyu Chen, Bixiang Zhang, Ming Huang, Hongming Liu, Yilei Mao, Ledu Zhou, Rui Wang, Yunfeng Shan, Wu Zhang, Tianqiang Song, Yabing Guo, Fuxiang Zhou, Bingfeng Shao, Mingjun Zhang, Bo Liang, Jinfang Zheng, Guoping Zhang, Jie Shen, Weiwen Su, Feng Zhang, Yifu He, Sheng Hu, Rong Liu, Chengwu Zhang, Shunli Shen, Hui Zeng, Tsang-En Wang, Wenzhi Guo, Yan Shen, Yajin Chen, Yong Li, J Samol, Hongtao Hu, Wenhua Zhang, Chengyou Du, Enxiao Li, Chao Liu, Choo Su Pin, Xun Li, Hao Xu, Jee-Fu Huang, Chunyi Hao, Jing Lv, Wei Wang, Qian Xu, Aobing Bai, Xiao Zhang, Bifeng Liu, Chunlei Jin, Jia Fan
You can read the Full Article on The Lancet Gastroenterology and Hepatology
More posts featuring Arndt Vogel.
